
FRIDAY, Sept. 22, 2023 (HealthDay News) – New research suggests some newer diabetes treatments may not be as beneficial for Black patients, after earlier drug trials included small numbers of non-white people. Whether the medications — called sodium-glucose co-transporter 2 inhibitors (SGLT2-Is) and glucogen-like peptide 1 receptor agonists (GLP1-Ras) — actually have less benefit for… read on > read on >